Portal Biotechnologies, headquartered in Watertown, MA, is a rapidly scaling cell-engineering platform company redefining how scientists and clinicians engineer cells across research, drug discovery, and therapeutic applications. Since launching its first product in 2024, Portal has built a network of 100+ active customers, including the top 10 global pharmaceutical companies and leading academic hospitals worldwide.

Backed by $24M in venture funding and an $8M DARPA contract, Portal’s proprietary mechanoporation technology transiently perturbs cell membranes as they pass through a silicon microstructure. This enables efficient multiplex delivery of diverse cargos such as RNA, proteins, small molecules, and gene-editing tools without compromising cell function. The approach is simple and scalable, supporting applications from high-throughput drug screening to clinical-scale manufacturing, and it works both as a stand-alone system and as an integrated component in third-party platforms.

The company’s growing product suite includes the Galaxy High-Throughput instrument, MilliBooster cartridges, and a DARPA-funded portable cell-engineering system launching in 2027. These offerings enable seamless scaling from R&D to point-of-care manufacturing. With a leadership team bringing decades of experience in clinical cell-therapy development and biotech operations, Portal is positioned to become the foundational backbone of cell engineering in both research and clinical settings.